Skip to main content
Log in

Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Murakami H, Irisawa H, Saitoh T, Matsushima T, Tamura J, Sawamura M, Karasawa M, Hosomura Y, Kojima M (1997) Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol 56:173–178

    Article  CAS  PubMed  Google Scholar 

  2. Fodor A, Molnar MZ, Krenacs L, Bagdi E, Csomor J, Matolcsy A, Demeter J (2009) Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma. Pathol Oncol Res (in press)

  3. Kalpadakis C, Pangalis GA, Dimopoulou MN, Vassilakopoulos TP, Kyrtsonis MC, Korkolopoulou P, Kontopidou FN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Tsaftaridis P, Plata E, Angelopoulou MK (2008) Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 26:114

    Article  Google Scholar 

  4. D’Arena G, Califano C, Annunziata M, Tartarone A, Capalbo S, Villani O, Amendola G, Pietrantuono G, Ferrara F, Pinto A, Musto P, D’Arco AM, Cascavilla N (2007) Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol 79:53–58

    Article  PubMed  Google Scholar 

  5. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456

    Article  CAS  PubMed  Google Scholar 

  6. Fabbri A, Gozzetti A, Lazzi S, Lenoci M, D’Amuri A, Leoncini L, Lauria F (2006) Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 6:496–499

    Article  PubMed  Google Scholar 

  7. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22:487–495

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Claudio Fozza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fozza, C., Galleu, A., Careddu, M.G. et al. Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma. Ann Hematol 89, 113–114 (2010). https://doi.org/10.1007/s00277-009-0782-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-009-0782-y

Keywords

Navigation